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E-mail address: wujstef@amg.gda.Abstract Background and aims: Pancreatic cancer is characterized by a constant
deterioration in quality of life, excruciating pain and progressive cachexia. The aim
of this study was to compare the effectiveness of two invasive methods of pain
treatment in these patients: neurolytic coeliac plexus block (NCPB) and videothor-
acoscopic splanchnicectomy (VSPL) to a conservatively treated control group
concerning pain, quality of life and opiates’ consumption.
Patients and methods: Fifty nine patients suffering from pain due to inoperable
pancreatic cancer were treated invasively with NCPB (NZ35) or VSPL (NZ24) in two
non-randomised, prospective, case-controlled protocols. Intensity of pain (VAS-
pain), quality of life (FACIT and QLQ C30) and opioid intake were compared between
the groups and to a control group of patients treated conservatively before the
procedure and after 2 and 8 weeks of follow-up. The analysis was performed
retrospectively using meta-analysis statistics.
Results: Both methods of invasive pain treatment resulted in significant reduction of
pain (VSPL effect sizeZ11.27, NCPB effect sizeZ7.29) and fatigue (effect sizes,
respectively, 1.23 and 3.37). NCPB improved also significantly physical, emotionalEJSO (2005) 31, 768–773
www.ejso.comElsevier Ltd. All rights reserved.
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Invasive pain treatment in pancreatic cancer—comparison 769and social well-being (effect sizes, respectively, 2.37, 4.13 and 7.51) which was not
observed after VSPL. No influence on ailments characteristic for the disease was
demonstrated. Mean daily opioid consumption was significantly decreased after both
procedures. There was no perioperative mortality and no major morbidity.
Conclusion: BothNCPBandVSPLprovide significant reductionofpainand improvement
of quality of life in inoperable pancreatic cancer patients. They present rather similar
efficacy, but lower invasiveness of NCPB, in combination with its more positive effect on
quality of life, pre-disposes it as being the preferred method.
Q 2005 Elsevier Ltd. All rights reserved.Introduction
The use of the stepwise World Health Organization
analgesic ladder is suggested as the analgesic
treatment in patients suffering from inoperable
pancreatic cancer (IPC).1–3 Often, the intensity of
pain is so high, that opiates are used extensively.
Although this approach should be applied in every
case when no alternative is available, it should be
mentioned that opiates present significant number
of physical and psychological complications, includ-
ing drowsiness, constipation, vomiting, deterior-
ated communication with family and depression.4,5
In rare cases of longer survival, iatrogenic addiction
can be observed, adding to the cachectic picture of
the disease.5 Thus, more invasive methods of pain
control need to be considered in IPC patients,
including neurolytic coeliac plexus block (NCPL)
and videothoracoscopic splanchnicectomy (VSPL).
Both methods have been well evaluated and
reportedly provide satisfactory long-term pain-
relief and decrease of the doses of opiates used.6–
8 The clinical relevance of pain reduction should be
also associated with the fact that pain decrease the
survival in pancreatic cancer patients.9 This is in
line with animal research demonstrating that pain
and stress appear to promote tumour growth and
result in increased mortality rates.10,11
The aim of the present study was to compare the
effectiveness of two invasive methods of pain
treatment in IPC patients—NCPB and VSPL—to a
conservatively treated control group. Unique of the
present study is that the comparison was not
limited to mere pain and the use of pain medi-
cation, but also broader aspects of quality of life
were included in the evaluation.Methods
Patients
Two groups of patients suffering from pain due toIPC were treated in two separate, case-controlled,
non-randomised studies including treatment with
VSPL or NCPB between January 2001 and September
2003 in Department of Surgery, Medical University
of Gdansk, Poland. The groups consisted of 14 men
and 10 women (VSPL group, NZ24, M:F ratioZ1.4)
with mean age of 63.5 years (range 47–78) and 21
men and 14 women (NCPB group, NZ35, M:F ratioZ
1.5) with mean age of 61.2 years (range 51–82). The
mean time since the diagnosis of the inoperability
of the disease was, respectively, 2.1 and 1.7
months, the time from the first symptoms of the
chronic pain syndrome was 3.2 and 2.5 months,
respectively. In 55 patients (32 in NCPB and 23 in
VSPL) the diagnosis was based on open biopsy, and
in 37 patients the palliative choledocho-jejunal and
gastro-jejunal anastomoses were fashioned before
qualifying to further analgesic treatment.
The choice of treatment was based on the
decision of the patients and NCPB was usually
chosen by patients suffering from pain for a shorter
period of time. This approach did not allow to
create randomized study but was in agreement with
consumeric (orientated towards patients’ needs)
approach to treatment and was considered more
ethical than randomization.
A control group of 39 patients with inoperable
pancreatic cancer who were treated conservatively
with standard analgesic therapy for chronic pain
were used for comparison. The mean age of the
group was 67.2 years (range: 52–82). The percen-
tage of women reached 41% similarly to other
groups. The onset of the disease was noted at
median time of 3.1 months before the initial
measurement.
The survival did not affect measures after 2
weeks, but 8 weeks measures could have been
taken in 21 (87.5%) patients from VSPL group, 31
(88.6%) from NCPB and 33 (84.6%) from the control
group.Measures
All groups were followed up and measures of pain
T. Stefaniak et al.770and quality of life were taken 2 and 8 weeks after
the intervention or in the case of the control group
at the corresponding period of time. The pain
measure included visual analogue scale-pain and
mean daily consumption of opiates quantified in
milligrams for all groups. Quality of life assessment
included functional assessment of cancer therapy
scale (pancreas version) in VSPL group and EORTC
QLQ-C30 score for NCPB group. The control group
was assessed with both FACIT and QLQ-C30.
Visual analog scale of pain (VAS-pain) is a
psychometric tool giving the patient opportunity
to express his/her subjective perception of pains,
she/he is feeling by drawing a line on a standardized
box printed on a sheet of paper. The distance from
the zero point to the end of the line drawn by the
patient is measured and calculated as a percentage
of the length of the box taken as a maximum.
Health-related quality of life is a psychological
parameter considered as a multi-factorial measure
including different aspects of well-being that may
be influenced by the illness. It usually incorporates
physical and emotional well-being, functional dis-
turbances, ailments typical for the disease and
indirect measure such as social support or fatigue.
FACIT and QLQ C-30 tools are well validated for
pancreatic cancer patients.12,13
Due to retrospective character of comparison
and separate character of protocols, the analytic
statistical techniques typically applied in meta-
analysis were employed in this study. Raw data was
compared using Student’ t-tests and ANOVA. For
meta-analytic like assessment fixed-effects method
was used, and effect sizes were calculated as the
difference between the outcome means of the
groups divided by the pooled standard deviations.
An overall weighted effect size was obtained and
presented with 95% confidence interval (95% CI).
Results were tested for homogeneity using the
Breslow–Day tests.Procedures
NCPB was performed similarly to the method
initially reported by Kappis14 in 1919. Patients
were placed in the prone Jack-knife position.
After the superficial anaesthesia with 1% ligno-
caine, the 20G needle (length 10–12 cm) was
introduced into the point located 5–7 cm laterally
from the midline, just under the lower margin of
the 12th rib, towards the trunk of L1, Th12
vertebrae. The canal of the needle was then
anaesthetized with further 6–10 ml of 1% ligno-
caine. The surface of the vertebra was usually
identified at a depth of 6–8 cm. Then, the needlewas rotated 908 towards the vertebra. When the
needle bypassed the vertebra by 1–2 cm, and after
ensuring it had not punctured the aorta or other
major vessel, 20–30 ml of 50% ethanol with 5 ml of
1% lignocaine was injected. The same procedure
was repeated for the contralateral side of the
vertebral column.
Unilateral VSPL was performed under general
anesthesia with single-bronchus intubation. The
patient was placed in the right lateral decubitus
position with the left arm elevated to 908 angle.
They were additionally fixed with support-arms and
bandages, and the table was then tilted 308
anteriorly in the longitudinal axis (thus, after
induction of a pneumothorax the lung would ‘fall
away’ from the costovertebral gutter). After
desufflation of the lung, two trocars were inserted
into the thorax: (1) a 5-mm trocar, was placed in
the fifth intercostal space in a medial axillary line
for the camera, and (2) a 5-mm trocar was placed in
the seventh intercostal space in an anterior axillary
line for the instruments. After identification of the
splanchnic nerve, the parietal pleura was incised
and the nerve, together with its minor connecting
branches, was prepared to a distance of 5–8 cm and
excised. After insufflation of the lung, the trocars
were removed, a single chest tube was placed, and
the wounds were closed according to standard
surgical technique.15Results
Both NCPB and VSPL were beneficial for the patients
with inoperable pancreatic cancer and resulted in a
better quality of life and less pain compared to
those patients treated conservatively, both after 2
and 8 weeks of follow-up. The results were
estimated basing on average effect size after 2
and 8 weeks of follow-up (Fig. 1).
The positive effect on pain was significantly
higher in the VSPL group, and the alleviation of VAS
scores was almost twice as strong after VSPL than
after the neurolysis. The impact of both procedures
on fatigue was significant in both groups, though it
was stronger in patients treated with the neuro-
lysis. Interestingly, improvement in social support
and emotional well-being was achieved only after
neurolysis, while VSPL had no impact on these
variables. The physical well-being improved signifi-
cantly only after NCPB, while there was no
influence of VSPL on this parameter. None of the
procedures had a positive effect on the ailments
typical for the illness.
Figure 1 Effect sizes of videothoracoscopic splanchnicectomy (VSPL) and neurolytic celiac plexus block (NCPB) in pain
treatment of inoperable pancreatic cancer pancreatitis patients compared to control group of patients treated
conservatively. Bars show mean effect sizes from two measures: after 2 and 8 weeks of follow-up with 95% CI indicated.
Invasive pain treatment in pancreatic cancer—comparison 771Table 1 represents the findings of the opiates’
consumption analysis.
There was no post-operative mortality and no
loss to follow-up at 2 weeks due to death. Thirteen
patients died before the 8-weeks assessment due to
their primary disease: four in NCPB group, three in
VSPL group and six in the control group (pZ0.744).
The only morbidity was observed in one VSPL
patient, who suffered from intermittent intercostal
nerve pain that resolved spontaneously after 2
weeks.Discussion
The current study compared retrospectively, in
meta-analytic fashion two most commonly utilized
techniques of invasive pain control in inoperative
pancreatic cancer, NCPB and VSPL. Although both
techniques have previously been shown to provide
significant benefit for the patients, no direct
comparison of them has ever been previously
attempted. The current results once moreTable 1 Opioid consumption in milligram (mean daily dose
8 weeks of follow-up




a t-Student significant comparison between two invasive treatme
b Statistically significant differences in ANOVA test comparing dif
c t-Student significant difference comparing invasively treated grdemonstrate that both methods result in a signifi-
cant short-term pain relief and improvement in
quality of life. Without precedence, however, is the
finding that, whereas NCPB affects most of the
parameters of quality of life, VSPL improves only
pain and fatigue. This limited positive effect of
VSPL may seem more convincing in light of previous
reports concerning chronic pancreatitis patients,15,
16 but, on the other hand, the influence of cancer
pain on every aspect of quality of life cannot be
denied. Achieving a reduction in patients’ pain
scores may improve their mood and further activity
and longevity. Similarly, in a study by Staats et al.
the neurolytic block, as compared with medical
management alone, not only improved pain, elev-
ated mood, reduced pain interference with
activity, but also, what is most encouraging, was
associated with an increase in life expectancy.17 In
a randomized study by Wong et al. comparing NCPB
and conservatively treated patients, only the
subjective perception of severity of pain was
improved which may have been subject to the
influence of patients’ expectations. Moreover, at 1
year, 16% of NCPB patients and 6% of opioid-onlyGstandard deviation) before the procedure and in 2 and





ferent follow-up points in the same group.
oup to the control group.
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reach statistical significance.18 Lillemoe et al.
reported that IPC patients treated with intraopera-
tive chemical splanchnicectomy during explorative
laparotomy experienced significantly lower pain
and had a lower opioid consumption compared to
control patients treated conservatively. In a group
of 34 patients with pain before laparotomy, survival
was improved in those receiving chemical
splanchnicectomy.8
The finding that NCPB has a positive effect on
emotional well-being is the more important since,
there is recent evidence showing that depression
may have a negative effect on immune functions
and antitumour therapy. This raises the intriguing
question whether this treatment is superior in
terms of survival in the long run as well.
New methods of imaging provide better and safer
approach to NCPB, though interpretation of US or
CT images may sometimes provide difficulties.19,20
The blind method of needle introduction presented
in our material did not produce any morbidity and
was successful in all 35 cases. Similarly, Firdousi
et al.21 presented 30 consecutive patients with
blind NCPB without mortality and significant mor-
bidity apart from transient hypotension. They
concluded that despite the proximity of vital
structures, blind unilateral retrocrural neurolytic
coeliac plexus blockade is a safe and effective
means to relieve terminal pain associated with
upper abdominal visceral cancer.21 Recently a
laparoscopic method of NCPB in an animal model
has been reported.22 It does, however, involve a
complex procedure combining laparoscopic ultra-
sound and endoscopy, thus requiring further research
before being considered a possible supplement to
pancreatic cancer laparoscopic staging.22
Videoscopic splanchnicectomy is also reported to
be safe and effective procedure in pain treatment
both in chronic pancreatitis and pancreatic cancer
patients.15,23–27 It is associated with low morbid-
ity23–27 and similarly to the current study, with good
results in terms of pain relief and improvement of
quality of life.23–27 In this study a unilateral
splanchnicectomy was chosen due to experience
of the surgeons performing the procedures.
The reduction of opioid consumption achieved in
the current study due to invasive treatment of pain
should not be underestimated. The influence of
opioid on escalation of adverse gastrointestinal
symptoms has been recently reported.5 Mercadante
et al. presented a prospective multicenter study, in
which 22 patients who underwent NCPB were
followed until death. NCPB was effective in redu-
cing opioid consumption and gastrointestinal
adverse effects for at least 4 weeks. In the last 4weeks prior to death, there was the typical trend of
increasing symptom intensity common to the
terminal cancer population.6 These results have
also been replicated elsewhere.7,28
Due to the short follow-up, the problem of
recurrent pain was not documented in the current
study. It does, however, have significant import-
ance to the clinical management of inoperable
pancreatic cancer patients. Vranken et al.29 per-
formed a post-mortem on two patients previously
treated with NCBP. The neurohistopathologic
examination of the celiac plexus revealed an
abnormal celiac architecture with a combination
of abnormal neurons with vacuolization and normal
looking neuronal structures (ganglionic structures
and nerve fibers) embedded in fibrotic hyalinized
tissue suggesting the neurolytic celiac plexus block
with alcohol was capable of partial and only partial
destruction of the celiac plexus.29
A solution to this problem may be provided by
insertion of celiac catheter. Vranken et al. reported
another study on 12 patients who underwent NCPB
with alcohol, administered via an indwelling celiac
catheter. Two patients remained without pain after
the first neurolytic celiac plexus block. In all other
patients a second block was administered which
provided only temporary relief. Additional intermit-
tent administration of bupivacaine through the
catheter was necessary to provide adequate pain
relief in these patients. Quality of life increased
significantly after the treatment. Opioid consump-
tion decreased in all patients. The authors concluded
that NCPB results in a significant but short-lasting
analgesic effect, but the use of a celiac catheter can
improve the long-term management.30
On the other hand, implantation of foreign
bodies such as catheters, carries a risk of infective
complications. One alternative would be to use a
combination of NCPB and unilateral or even
bilateral VSPL. Although, the optimal timing of
these interventions remains to be determined,
considering that 80–88% of inoperable pancreatic
cancer patients present with or eventually develop
intractable pain29 and invasive methods of pain
relief are associated with minimal morbidity, a case
could be made for elective NCPB and/or VSPL.
The limitations of the current study include the
relatively small numbers of patients, the retro-
spective nature, lack of randomization associated
with the non-standardized analysis of the quality of
life and short follow-up period. Despite this, the
results indicate a significant short-term benefit for
those undergoing invasive intervention for pain in
inoperable pancreatic cancer. Further studies
including longer follow-up and survival analysis
Invasive pain treatment in pancreatic cancer—comparison 773with standardized quality of life would be particu-
larly useful.
In conclusion, the present findings suggest that
both NCPB and VSPL provide significant reduction of
pain and improvement of quality of life in inoper-
able pancreatic cancer patients. They present
rather similar efficacy, but the lower invasiveness
of NCPB predisposes it to earlier administration.
Given the fact that this method also appears to have
a positive effects on broader aspects of quality of
life, this is sufficient reason to recommend NCPB as
more preferred method.
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